Merck’s 2025 revenue forecast fell short of Wall Street expectations, following the company’s decision to temporarily halt shipments of its cancer vaccine, Gardasil, to China, CNBC reported Feb. 4.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
